An Italian Multicenter Retrospective Real-life Analysis of Patients with Brain Metastases from Renal Cell Carcinoma: the BMRCC Study

Overview

Journal ESMO Open

Publisher Elsevier

Specialty Oncology

Date 2023 Jul 19

PMID 37467658

Authors

V Interno

F Massari

R Ruda

B A Maiorano

O Caffo

G Procopio

S Bracarda

F Atzori

A Passarelli

M Bersanelli

M Stellato

G Fornarini

L Galli

C Ortega

E Zanardi

L Incorvaia

G Facchini

J R Giron Berrios

R Ricotta

M Santoni

C Funaioli

P Trerotoli

C Porta

M Rizzo

Affiliations

Soon will be listed here.

Abstract

Background: The treatment of patients with brain-spread renal cell carcinoma (RCC) is an unmet clinical need, although more recent therapeutic strategies have significantly improved RCC patients' life expectancy. Our multicenter, retrospective, observational study investigated a real-world cohort of patients with brain metastases (BM) from RCC (BMRCC).

Patients And Methods: A total of 226 patients with histological diagnosis of RCC and radiological evidence of BM from 22 Italian institutions were enrolled. Univariate and multivariate models were performed to investigate the impact of clinicopathological features and multimodal treatments on both overall survival (OS) from the BM diagnosis and intracranial progression-free survival (iPFS).

Results: The median OS from the BM diagnosis was 18.8 months (interquartile range: 6.2-43 months). Multivariate analysis confirmed the following as positive independent prognostic factors: a Karnofsky Performance Status >70% [hazard ratio (HR) = 0.49, 95% confidence interval (CI) 0.26-0.92, P = 0.0026] and a single BM (HR = 0.51, 95% CI 0.31-0.86, P = 0. 0310); in contrast, the following were confirmed as worse prognosis factors: progressive extracranial disease (HR = 1.66, 95% CI 1.003-2.74, P = 0.00181) and only one line of systemic therapy after the BM occurrence (HR = 2.98, 95% CI 1.62-5.49, P = 0.029). Subgroup analyses showed no difference in iPFS according to the type of the first systemic treatment [immunotherapy (IT) or targeted therapy (TT)] carried out after the BM diagnosis (HR = 1.033, 95% CI 0.565-1.889, P = 0.16), and revealed that external radiation therapy (eRT) significantly prolonged iPFS when combined with IT (10.7 months, 95% CI 4.9-48 months, P = 0.0321) and not when combined with TT (9.01 months, 95% CI 2.7-21.2 months, P = 0.59).

Conclusions: Our results suggest a potential additive effect in terms of iPFS for eRT combined with IT and encourage a more intensive multimodal therapeutic strategy in a multidisciplinary context to improve the survival of BMRCC patients.

Citing Articles

Clinical outcome predictors for metastatic renal cell carcinoma: a retrospective multicenter real-life case series.

Rizzo M, Pezzicoli G, Tibollo V, Premoli A, Quaglini S BMC Cancer. 2024; 24(1):804.

PMID: 38970009 PMC: 11225140. DOI: 10.1186/s12885-024-12572-4.

References

Okada H, Weller M, Huang R, Finocchiaro G, Gilbert M, Wick W . Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015; 16(15):e534-e542. PMC: 4638131. DOI: 10.1016/S1470-2045(15)00088-1. View

Hanzly M, Abbotoy D, Creighton T, Diorio G, Mehedint D, Murekeyisoni C . Early identification of asymptomatic brain metastases from renal cell carcinoma. Clin Exp Metastasis. 2015; 32(8):783-8. DOI: 10.1007/s10585-015-9748-8. View

El Ali Z, Rottey S, Barthelemy P, Kotecki N, Van Paemel R, Devrient D . Brain Metastasis and Renal Cell Carcinoma: Prognostic Scores Assessment in the Era of Targeted Therapies. Anticancer Res. 2019; 39(6):2993-3002. DOI: 10.21873/anticanres.13431. View

Hasanov E, Yeboa D, Tucker M, Swanson T, Beckham T, Rini B . An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA Cancer J Clin. 2022; 72(5):454-489. DOI: 10.3322/caac.21729. View

Sperduto P, Mesko S, Li J, Cagney D, Aizer A, Lin N . Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. J Clin Oncol. 2020; 38(32):3773-3784. PMC: 7655019. DOI: 10.1200/JCO.20.01255. View

Suarez-Sarmiento Jr A, Nguyen K, Syed J, Nolte A, Ghabili K, Cheng M . Brain Metastasis From Renal-Cell Carcinoma: An Institutional Study. Clin Genitourin Cancer. 2019; 17(6):e1163-e1170. DOI: 10.1016/j.clgc.2019.08.006. View

Grande Pulido E, Martin Centeno A, Maroto Rey P, Narbon E . [Molecular biology of the clear cell renal cell carcinoma: principles for a selective treatment]. Actas Urol Esp. 2007; 31(3):233-43. DOI: 10.1016/s0210-4806(07)73628-8. View

Wei H, Miao J, Cui J, Zheng W, Chen X, Zhang Q . The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database. Sci Rep. 2021; 11(1):17822. PMC: 8426479. DOI: 10.1038/s41598-021-97365-6. View

Chandrasekar T, Klaassen Z, Goldberg H, Kulkarni G, Hamilton R, Fleshner N . Metastatic renal cell carcinoma: Patterns and predictors of metastases-A contemporary population-based series. Urol Oncol. 2017; 35(11):661.e7-661.e14. DOI: 10.1016/j.urolonc.2017.06.060. View

10.

Camidge D, Lee E, Lin N, Margolin K, Ahluwalia M, Bendszus M . Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018; 19(1):e20-e32. DOI: 10.1016/S1470-2045(17)30693-9. View

11.

De Giorgi U, Carteni G, Giannarelli D, Basso U, Galli L, Cortesi E . Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. BJU Int. 2018; 123(1):98-105. DOI: 10.1111/bju.14461. View

12.

Wolchok J, Hoos A, ODay S, Weber J, Hamid O, Lebbe C . Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15(23):7412-20. DOI: 10.1158/1078-0432.CCR-09-1624. View

13.

Interno V, De Santis P, Stucci L, Ruda R, Tucci M, Soffietti R . Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview. Cancers (Basel). 2021; 13(9). PMC: 8123796. DOI: 10.3390/cancers13092114. View

14.

Rizzo M, Porta C . Concurrent Stereotactic Ablative Radiotherapy and Antiangiogenic Targeted Agents: Redefining the Therapeutic Strategy. Eur Urol Oncol. 2022; 6(2):212-213. DOI: 10.1016/j.euo.2022.11.001. View

15.

Chukwueke U, Wen P . Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol. 2019; 8(1):CNS28. PMC: 6499019. DOI: 10.2217/cns-2018-0007. View

16.

Santoni M, Conti A, Procopio G, Porta C, Ibrahim T, Barni S . Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. J Exp Clin Cancer Res. 2015; 34:10. PMC: 4328067. DOI: 10.1186/s13046-015-0122-0. View

17.

Wardak Z, Christie A, Bowman A, Stojadinovic S, Nedzi L, Barnett S . Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma. Clin Genitourin Cancer. 2019; 17(2):e273-e280. PMC: 6563340. DOI: 10.1016/j.clgc.2018.11.006. View

18.

Canino C, Perrone L, Bosco E, Saltalamacchia G, Mosca A, Rizzo M . Targeting angiogenesis in metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2019; 19(3):245-257. DOI: 10.1080/14737140.2019.1574574. View

19.

Cagney D, Martin A, Catalano P, Redig A, Lin N, Lee E . Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017; 19(11):1511-1521. PMC: 5737512. DOI: 10.1093/neuonc/nox077. View

20.

Weichselbaum R, Liang H, Deng L, Fu Y . Radiotherapy and immunotherapy: a beneficial liaison?. Nat Rev Clin Oncol. 2017; 14(6):365-379. DOI: 10.1038/nrclinonc.2016.211. View